Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCoP: Sertindole vs Risperidone Safety Study
NCT00856583Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Jul 2002
- Primary completion
- Feb 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sertindole in schizophrenia (2 arms), sponsored by Lundbeck. Primary endpoints: Number of Participants With All-cause Mortality at 14 months and Number of Participants With Cardiac Events, Including Arrhythmias, Requiring Hospitalisation at 14 months. Started Jul 2002; status: completed.
02
Drugs
sertindole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00856583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00856583.